MAP2 and Parkinson disease: PEA blunted Aβ42-induced reduction in MAP-2 labeling in degenerating neurons in vitro (Beggiato et al., 2018) and attenuated MAP-2 deficit in an in vivo Parkinson’s disease (PD) model (PEA 10 mg/kg) (Esposito et al., 2012).